Observational studyBreast (Edinburgh, Scotland)2026
Effect of adjuvant endocrine therapy on recurrence and contralateral breast cancer in HR-positive DCIS after mastectomy.
Observational study in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical benefits of adjuvant endocrine therapy for patients with hormone receptor (HR)-positive ductal carcinoma in situ (DCIS) undergoing mastectomy remain controversial. While endocrine therapy is known to reduce recurrence after breast-conserving surgery, its role post-mastectomy is unclear. We aimed to assess the impact of adjuvant endocrine therapy on recurrence and contralateral breast cancer (CBC) in patients with HR-positive DCIS treated with mastectomy.
methodsIn this retrospective multicenter cohort study, we included patients with HR-positive, pure DCIS who underwent mastectomy between 2003 and 2018 across three cancer centers in South Korea. Patients were stratified based on receipt of adjuvant endocrine therapy (ETx). Logistic regression and Cox proportional hazards models were used to evaluate associations between ETx and recurrence or CBC. Annual hazard rates were estimated using kernel-smoothed functions.
resultsOf 1,186 eligible patients, 599 (50.5 %) received endocrine therapy. Median follow-up was 86.3 months. The recurrence rate was significantly lower in the ETx group compared to no-ETx (7.0 % vs. 11.7 %; OR, 0.57; p = 0.005). Locoregional recurrence was also lower (2.5 % vs. 4.8 %; OR, 0.51; p = 0.04). CBC occurred in 5.3 % overall, with a non-significant reduction in the ETx group (4.2 % vs. 6.5 %; OR, 0.63; p = 0.08). In multivariable Cox models, ETx was associated with reduced recurrence (HR, 0.53; p = 0.01) and CBC (HR, 0.53; p = 0.04). Risk reduction persisted beyond 10 years.
conclusionAdjuvant endocrine therapy was associated with significant reductions in recurrence and CBC risk after mastectomy for HR-positive DCIS, supporting selective use based on individual risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.